Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has a tradeable public float of approximately 387,072 American Depositary Shares following a 1-for-10 reverse split effective August 21, 2026. Pending dilutive supply totals roughly 2.27 million ADSs — about 5.9 times that float — earning the company a dilution risk score of 9 out of 10.
The single largest overhang is structural, not hypothetical. Three institutional holders — Armistice Capital, Intracoastal Capital and RK Stone Miami — collectively hold 531,328 post-split ADSs in pre-funded warrants, a type of warrant struck at a nominal price (here, $0.001 to $0.01 per ADS) so that the holder has economically already paid for the stock and can convert to sellable shares on demand. That block alone equals 137% of the entire float. All of the underlying ADSs were registered for resale on an F-3 filing that became effective May 19, 2026. The selling-shareholder tables in the prospectus show Armistice and Intracoastal each retaining zero ADSs after the offering — a stated intent to liquidate every share into the open market.
Beneficial-ownership blockers — contractual caps of 4.99% or 9.99% — limit how many shares any single holder can own at once. They meter the flow. They do not cap total supply, because each block sold frees capacity to exercise more.
The Equity Line
A second critical mechanism went live around August 17. The company signed a $15 million Standby Equity Purchase Agreement — a committed credit-like facility where the company can periodically sell new ADSs to a single buyer — with Yorkville Advisors in September 2025. The pricing: 97% of the lowest daily volume-weighted average price over a three-trading-day window, meaning Yorkville pays a 3% discount to the weakest session in each look-back period. The company has already registered 480,000 post-split ADSs for Yorkville's resale, equal to 124% of the current float. A predecessor $10 million facility was drawn roughly $5.8 million in five months, demonstrating consistent usage.
A 90-day restriction on new variable-rate issuances — imposed by the April 2026 PIPE investors — expired around August 17, four days before this assessment. The equity line is now live again.
Realized Dilution and the Split Cycle
SCNI's ordinary-share count grew from 3.41 billion to 13.87 billion during calendar 2025 — a 306.6% increase — then climbed another 14% to 15.84 billion by May 2026. The company has executed three 1-for-10 reverse splits since late 2022, producing a cumulative 1-for-1,000 compression. Each split was followed by renewed issuance.
The pattern extends to warrant repricing. In April 2026, Armistice's January 2024 warrants were repriced from $6.50 to $0.48 per ADS — a 92.6% strike reduction — and Armistice received an additional 45,862 post-split Inducement Warrants as consideration. A similar repricing occurred in December 2023. Currently outstanding Series A, Series B and Inducement warrants totaling 1,113,570 post-split ADSs carry strikes of $4.80 to $5.50; based on the issuer's own precedent, out-of-the-money paper at this company has been renegotiated downward rather than allowed to expire.
Authorized Headroom
The company has 1,000,000 post-split ADSs authorized against 395,979 outstanding — but fully diluted supply of approximately 2.18 million ADSs would require roughly 87 billion ordinary shares, more than double the 40 billion currently authorized. Any full exercise of the outstanding instruments would first require a shareholder vote to raise the ceiling or another ADS-ratio change.
Every data-service float quote for this ticker is a lagging floor: the feeds have not yet incorporated the August 2026 reverse split in the outstanding field, the May 2026 resale registration, or any pre-funded warrant exercises after May 5.